Brain and cancer: the protective role of erythropoietin

Giovanni Grasso, Giovanni Grasso, Emanuela Cavallaro, Fulvio Floccari, Michele Buemi, Lorena Nostro, Chiara Caccamo

Risultato della ricerca: Article

30 Citazioni (Scopus)

Abstract

Erythropoietin (Epo) is a pleiotropic agent, that is to say, it can act on several cell types indifferent ways. An independent system Epo/Epo receptor (EpoR) was detected in brain, leading tothe hypothesis that this hormone could be involved in cerebral functions. Epo/EpoR expressionchanges during ontogenesis, thus indicating the importance of this system in neurodevelopment.Moreover, the hypoxia-induced production of Epo in the adult brain suggests that it could exert aneurotrophic and neuroprotective effect in case of brain injury. Epo could also influence neuro-transmission, inducing neurotransmitters (NT) release. Epo therapy in anemic cancer patients isstill a controversial issue, because of its possible action as a growth and an angiogenic factor. In ourspeculative hypothesis Epo could be involved in a ‘‘two steps process’’ that, after a neo-vascularization phase, leads to its down regulation. Moreover, Epo-activated signaling pathwayscould be modulated as possible targets to interfere in neoplastic cells cycle. In conclusion,treatment with rHuEpo could change therapeutical perspectives in different pathological condi-tions, such as central nervous system (CNS) diseases, but further studies are needed to clarify itsphysiopathological activities in different clinical fields.
Lingua originaleEnglish
pagine (da-a)245-259
Numero di pagine15
RivistaMedicinal Research Reviews
Volume25
Stato di pubblicazionePublished - 2005

Fingerprint

Erythropoietin
Brain Neoplasms
Erythropoietin Receptors
Angiogenesis Inducing Agents
Central Nervous System Diseases
Brain
Neuroprotective Agents
Brain Injuries
Neurotransmitter Agents
Intercellular Signaling Peptides and Proteins
Cell Cycle
Down-Regulation
Hormones
Therapeutics
Neoplasms

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Cita questo

Grasso, G., Grasso, G., Cavallaro, E., Floccari, F., Buemi, M., Nostro, L., & Caccamo, C. (2005). Brain and cancer: the protective role of erythropoietin. Medicinal Research Reviews, 25, 245-259.

Brain and cancer: the protective role of erythropoietin. / Grasso, Giovanni; Grasso, Giovanni; Cavallaro, Emanuela; Floccari, Fulvio; Buemi, Michele; Nostro, Lorena; Caccamo, Chiara.

In: Medicinal Research Reviews, Vol. 25, 2005, pag. 245-259.

Risultato della ricerca: Article

Grasso, G, Grasso, G, Cavallaro, E, Floccari, F, Buemi, M, Nostro, L & Caccamo, C 2005, 'Brain and cancer: the protective role of erythropoietin', Medicinal Research Reviews, vol. 25, pagg. 245-259.
Grasso G, Grasso G, Cavallaro E, Floccari F, Buemi M, Nostro L e altri. Brain and cancer: the protective role of erythropoietin. Medicinal Research Reviews. 2005;25:245-259.
Grasso, Giovanni ; Grasso, Giovanni ; Cavallaro, Emanuela ; Floccari, Fulvio ; Buemi, Michele ; Nostro, Lorena ; Caccamo, Chiara. / Brain and cancer: the protective role of erythropoietin. In: Medicinal Research Reviews. 2005 ; Vol. 25. pagg. 245-259.
@article{f56340085aa84edb87131f5f85f5acb8,
title = "Brain and cancer: the protective role of erythropoietin",
abstract = "Erythropoietin (Epo) is a pleiotropic agent, that is to say, it can act on several cell types indifferent ways. An independent system Epo/Epo receptor (EpoR) was detected in brain, leading tothe hypothesis that this hormone could be involved in cerebral functions. Epo/EpoR expressionchanges during ontogenesis, thus indicating the importance of this system in neurodevelopment.Moreover, the hypoxia-induced production of Epo in the adult brain suggests that it could exert aneurotrophic and neuroprotective effect in case of brain injury. Epo could also influence neuro-transmission, inducing neurotransmitters (NT) release. Epo therapy in anemic cancer patients isstill a controversial issue, because of its possible action as a growth and an angiogenic factor. In ourspeculative hypothesis Epo could be involved in a ‘‘two steps process’’ that, after a neo-vascularization phase, leads to its down regulation. Moreover, Epo-activated signaling pathwayscould be modulated as possible targets to interfere in neoplastic cells cycle. In conclusion,treatment with rHuEpo could change therapeutical perspectives in different pathological condi-tions, such as central nervous system (CNS) diseases, but further studies are needed to clarify itsphysiopathological activities in different clinical fields.",
keywords = "Angiogenesis, Cancer, Erythropoietin, Hypoxia, Medicine (all), Neuroprotection, Organic Chemistry, Pharmacology, Pleiotropy",
author = "Giovanni Grasso and Giovanni Grasso and Emanuela Cavallaro and Fulvio Floccari and Michele Buemi and Lorena Nostro and Chiara Caccamo",
year = "2005",
language = "English",
volume = "25",
pages = "245--259",
journal = "Medicinal Research Reviews",
issn = "0198-6325",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Brain and cancer: the protective role of erythropoietin

AU - Grasso, Giovanni

AU - Grasso, Giovanni

AU - Cavallaro, Emanuela

AU - Floccari, Fulvio

AU - Buemi, Michele

AU - Nostro, Lorena

AU - Caccamo, Chiara

PY - 2005

Y1 - 2005

N2 - Erythropoietin (Epo) is a pleiotropic agent, that is to say, it can act on several cell types indifferent ways. An independent system Epo/Epo receptor (EpoR) was detected in brain, leading tothe hypothesis that this hormone could be involved in cerebral functions. Epo/EpoR expressionchanges during ontogenesis, thus indicating the importance of this system in neurodevelopment.Moreover, the hypoxia-induced production of Epo in the adult brain suggests that it could exert aneurotrophic and neuroprotective effect in case of brain injury. Epo could also influence neuro-transmission, inducing neurotransmitters (NT) release. Epo therapy in anemic cancer patients isstill a controversial issue, because of its possible action as a growth and an angiogenic factor. In ourspeculative hypothesis Epo could be involved in a ‘‘two steps process’’ that, after a neo-vascularization phase, leads to its down regulation. Moreover, Epo-activated signaling pathwayscould be modulated as possible targets to interfere in neoplastic cells cycle. In conclusion,treatment with rHuEpo could change therapeutical perspectives in different pathological condi-tions, such as central nervous system (CNS) diseases, but further studies are needed to clarify itsphysiopathological activities in different clinical fields.

AB - Erythropoietin (Epo) is a pleiotropic agent, that is to say, it can act on several cell types indifferent ways. An independent system Epo/Epo receptor (EpoR) was detected in brain, leading tothe hypothesis that this hormone could be involved in cerebral functions. Epo/EpoR expressionchanges during ontogenesis, thus indicating the importance of this system in neurodevelopment.Moreover, the hypoxia-induced production of Epo in the adult brain suggests that it could exert aneurotrophic and neuroprotective effect in case of brain injury. Epo could also influence neuro-transmission, inducing neurotransmitters (NT) release. Epo therapy in anemic cancer patients isstill a controversial issue, because of its possible action as a growth and an angiogenic factor. In ourspeculative hypothesis Epo could be involved in a ‘‘two steps process’’ that, after a neo-vascularization phase, leads to its down regulation. Moreover, Epo-activated signaling pathwayscould be modulated as possible targets to interfere in neoplastic cells cycle. In conclusion,treatment with rHuEpo could change therapeutical perspectives in different pathological condi-tions, such as central nervous system (CNS) diseases, but further studies are needed to clarify itsphysiopathological activities in different clinical fields.

KW - Angiogenesis

KW - Cancer

KW - Erythropoietin

KW - Hypoxia

KW - Medicine (all)

KW - Neuroprotection

KW - Organic Chemistry

KW - Pharmacology

KW - Pleiotropy

UR - http://hdl.handle.net/10447/19089

M3 - Article

VL - 25

SP - 245

EP - 259

JO - Medicinal Research Reviews

JF - Medicinal Research Reviews

SN - 0198-6325

ER -